George K. Ng
CIK: 0001638744
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Aug 8, 2026PCSA
Processa Pharmaceuticals, Inc.
Exercise(M)Direct1.6K shares- - Jul 26, 2026PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
9.4K shares- - Jul 1, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct3.1K shares at avg. $1.93$6K - Jun 15, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct2.5K shares at avg. $2.22$5K - May 29, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct2.1K shares at avg. $2.57$5K - May 15, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct1.8K shares at avg. $2.97$5K - Apr 30, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct2K shares at avg. $2.69$5K - Apr 15, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct1.8K shares at avg. $2.97$5K - Mar 31, 2026PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Direct2.1K shares at avg. $2.54$5K - Feb 12, 2026HURA
TuHURA Biosciences, Inc./NV
Award(A)DirectOptions (Right to Buy)
156.2K shares- - Oct 1, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectStock Options (Right to Buy)
768K shares- - Oct 1, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
256K shares- - Jul 24, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
1.8M shares- - Jan 29, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)IndirectWarrants
43.6K shares- - Jan 29, 2025PCSA
Processa Pharmaceuticals, Inc.
Award(A)IndirectWarrants
87.2K shares- - Jan 27, 2025PCSA
Processa Pharmaceuticals, Inc.
Purchase(P)Indirect87.2K shares at avg. $0.80$70K - Jan 2, 2025HURA
TuHURA Biosciences, Inc./NV
Award(A)DirectOptions (Right to Buy)
51.3K shares- - Oct 18, 2024KTRA
Kintara Therapeutics, Inc.
Award(A)DirectOptions (Right to Buy)
35.8K shares- - Oct 18, 2024KTRA
Kintara Therapeutics, Inc.
Award(A)DirectOptions (Right to Buy)
13.6K shares- - Oct 18, 2024KTRA
Kintara Therapeutics, Inc.
Award(A)DirectOptions (Right to Buy)
13.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 8, 2026 |  PCSA Processa Pharmaceuticals, Inc. | Exercise(M) | 1,600 | - | $0 | Direct |
| Jul 26, 2026 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 9,384 | - | - | Direct |
| Jul 1, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 3,057 | $1.93 | $5,900 | Direct |
| Jun 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 2,465 | $2.22 | $5,472 | Direct |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 2,129 | $2.57 | $5,472 | Direct |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 1,843 | $2.97 | $5,474 | Direct |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 2,034 | $2.69 | $5,471 | Direct |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 1,843 | $2.97 | $5,474 | Direct |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 2,136 | $2.54 | $5,415 | Direct |
| Feb 12, 2026 |  HURA TuHURA Biosciences, Inc./NV | Award(A) Options (Right to Buy) | 156,240 | - | - | Direct |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Stock Options (Right to Buy) | 768,000 | - | - | Direct |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 256,000 | - | - | Direct |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 1,822,471 | - | - | Direct |
| Jan 29, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Warrants | 43,600 | - | - | Indirect |
| Jan 29, 2025 | PCSA Processa Pharmaceuticals, Inc. | Award(A) Warrants | 87,200 | - | - | Indirect |
| Jan 27, 2025 | PCSA Processa Pharmaceuticals, Inc. | Purchase(P) | 87,200 | $0.80 | $69,542 | Indirect |
| Jan 2, 2025 | HURA TuHURA Biosciences, Inc./NV | Award(A) Options (Right to Buy) | 51,275 | - | - | Direct |
| Oct 18, 2024 |  KTRA Kintara Therapeutics, Inc. | Award(A) Options (Right to Buy) | 35,780 | - | - | Direct |
| Oct 18, 2024 | KTRA Kintara Therapeutics, Inc. | Award(A) Options (Right to Buy) | 13,553 | - | - | Direct |
| Oct 18, 2024 | KTRA Kintara Therapeutics, Inc. | Award(A) Options (Right to Buy) | 13,553 | - | - | Direct |
1-20 of 20 transactions
About Ng George K
Ng George K (SEC CIK 0001638744) files insider reports with the SEC as Chief Executive Officer of Processa Pharmaceuticals, Inc. (PCSA) and Director of TuHURA Biosciences, Inc./NV (HURA).
Signal8 holds 21 ownership filings by Ng George K (1 Form 3, 20 Form 4), filed between Oct 22, 2024 and Aug 11, 2026. Those filings report 20 transactions, from Oct 18, 2024 to Aug 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ng George K's filings is in VERO BEACH, FL.
Recent filings by Ng George K
- Aug 8, 2026: Option exercise of PCSA shares (Form 4, code M).
- Jul 26, 2026: Grant or award of PCSA derivative securities (Form 4, code A).
- Jul 1, 2026: Open-market purchase of PCSA shares (Form 4, code P).
- Jun 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
- May 29, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)
- GUJRATHI SHEILA, Director
- Yorke Justin W, Director
- SKIBSTED RUSSELL, Chief Financial Officer
- Pannu Geraldine, Director
- Neal James R, Director
- Lin Patrick, Chief Business - Strategy Off